This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
New book sets the pharmaceutical industry on a course for bridging the patient centricity optimism gap. That’s according to Sharon Suchotliff, patient centricity lead at consultancy firm ZS Associates, which has just published a book on the art of patient involvement. Patient centricity is not a new conversation in pharma.
Patents are often described as the ‘lifeblood’ of pharmaceuticalcompanies. 1 However, patent protection for pharmaceutical products is an economic trade-off between providing monopoly rights that incentivise development of future products and permitting higher drug prices to recoup the investment. 2020-02-24.
This allows pharmaceuticalcompanies to maintain their brand voice and facilitates information sharing. Many aspiring medical writers falsely believe they should market their services only to pharmaceutical and medical device companies. All their claims are well-researched and supported by data.
” Tony Cundell: Contract manufacturing organisations (CROs), start-up companies, established pharmaceuticalcompanies and regulatory agencies are having difficulty recruiting and retaining technically-trained personnel. About the authors.
As a renowned chemist, Dr. Senanayake discussed the need to adopt green chemistry in the process of drugdevelopment for cost reduction, timely innovation, and generating less waste than the standard process. According to me the main issue faced during the pandemic was the supply chain of pharmaceuticals.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content